Search Results

MC# 14-06
A Multicenter, Phase I/Ib, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors

MC# 14-30
Phase II Study Of Combined Targeted P53 Gene Therapy (SGT-53) Plus Gemcitabine/Nab-Paclitaxel For Treatment Of Metastatic Pancreatic Cancer

MC# 16-02
A Four Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination with Weekly Paclitaxel; Part A: A Dose-Escalation Study in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Part B: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Part C: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal or Gastro-esophageal Junction Adenocarcinoma; Part D: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Squamous Cell Cancer

MC# 16-03
A Phase Ib Study of an Immunotherapeutic Vaccine, DPX-Survivac with Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients with Recurrent Ovarian Cancer.

MC# 16-08
A Phase I/II Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer

MC# 16-14
A Phase I/Ib, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

MC# 16-31
A Phase I Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination with MEDI4736 in Adult Subjects with Select Advanced Solid Tumors

MC# 17-01
A Phase I Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors

MC# 17-03
A Phase II Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With or Without Gemcitabine as Second/Third-Line Therapy in Advanced Pancreatic Cancer Patients

MC# 17-35
A Phase I/II open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab (SAR650984) in combination with REGN2810 or isatuximab alone in patients with advanced malignancies

MC# 18-12
A Phase I/II Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination with Pembrolizumab in the Treatment of Patients with Extensive Disease (ED) Small Cell Lung Cancer (SCLC

MC# 18-16
Randomized, double-blind, placebo controlled, dose finding Phase II study comparing oral daily dosing of VERU-944 after a week of loading (daily dosing) with placebo to ameliorate the vasomotor symptoms resulting from androgen deprivation therapy in men with advanced prostate cancer

MC# 18-18
A Phase II, Randomized, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination with Avelumab and Carboplatin in Comparison to Standard of Care Therapy in Participants with PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

MC# 15-31
A Phase Ib/II, Open-label, Multicenter, Dose-escalation and expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma

MC# 16-32
A Phase I/IIA, Multi Center, Open-label Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer

MC# 17-05
A Phase I, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors

MC# 17-09
A Phase I Study of Intra-peritoneal Cantrixil in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

MC# 18-05
A Phase I Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients with Advanced Solid Tumors

MC# 17-36
First-in-Human, Open-Label, Dose-Escalation Trial with Expansion Cohorts to Evaluate Safety of Axl-Specific Antibody-Drug Conjugate (HuMax®-AXL-ADC) in Patients with Solid Tumors

MC# 17-13
A Phase I/II Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination with Immune Therapies in Subjects With Advanced or Metastatic Malignancies

MC# 18-02
A phase I, open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK3326595 in subjects with solid tumors and non- Hodgkin’s lymphoma

MC# 18-17
- A Phase I Study of RGX-202, a Small Molecule Inhibitor of the Creatine Transporter, SLC6a8, with or without FOLFIRI in Patients with Advanced Gastrointestinal Malignancies with Select Expansion Cohorts

MC# 15-03
A Phase I/II, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

MC# 16-29
An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

MC# 17-37
A Phase I/IIa Study of BMS-986179 Administered Alone and in Combination with Nivolumab (BMS-936558) in Subjects with Advanced Solid Tumors